nodes	percent_of_prediction	percent_of_DWPC	metapath
Lisdexamfetamine—Mydriasis—Prednisolone—ankylosing spondylitis	0.0145	0.0145	CcSEcCtD
Lisdexamfetamine—Sudden death—Methotrexate—ankylosing spondylitis	0.0137	0.0137	CcSEcCtD
Lisdexamfetamine—Mania—Betamethasone—ankylosing spondylitis	0.0133	0.0133	CcSEcCtD
Lisdexamfetamine—Mania—Dexamethasone—ankylosing spondylitis	0.0133	0.0133	CcSEcCtD
Lisdexamfetamine—Mania—Prednisone—ankylosing spondylitis	0.0115	0.0115	CcSEcCtD
Lisdexamfetamine—Euphoric mood—Prednisolone—ankylosing spondylitis	0.00992	0.00992	CcSEcCtD
Lisdexamfetamine—Euphoric mood—Triamcinolone—ankylosing spondylitis	0.00913	0.00913	CcSEcCtD
Lisdexamfetamine—Euphoric mood—Methylprednisolone—ankylosing spondylitis	0.00911	0.00911	CcSEcCtD
Lisdexamfetamine—Visual disturbance—Prednisolone—ankylosing spondylitis	0.00885	0.00885	CcSEcCtD
Lisdexamfetamine—Euphoric mood—Dexamethasone—ankylosing spondylitis	0.00828	0.00828	CcSEcCtD
Lisdexamfetamine—Euphoric mood—Betamethasone—ankylosing spondylitis	0.00828	0.00828	CcSEcCtD
Lisdexamfetamine—Affect lability—Prednisolone—ankylosing spondylitis	0.00825	0.00825	CcSEcCtD
Lisdexamfetamine—Affect lability—Triamcinolone—ankylosing spondylitis	0.00759	0.00759	CcSEcCtD
Lisdexamfetamine—Affect lability—Methylprednisolone—ankylosing spondylitis	0.00757	0.00757	CcSEcCtD
Lisdexamfetamine—Psychotic disorder—Methylprednisolone—ankylosing spondylitis	0.00751	0.00751	CcSEcCtD
Lisdexamfetamine—Visual disturbance—Betamethasone—ankylosing spondylitis	0.00738	0.00738	CcSEcCtD
Lisdexamfetamine—Visual disturbance—Dexamethasone—ankylosing spondylitis	0.00738	0.00738	CcSEcCtD
Lisdexamfetamine—Irritability—Methylprednisolone—ankylosing spondylitis	0.00734	0.00734	CcSEcCtD
Lisdexamfetamine—Euphoric mood—Prednisone—ankylosing spondylitis	0.00721	0.00721	CcSEcCtD
Lisdexamfetamine—Affect lability—Dexamethasone—ankylosing spondylitis	0.00689	0.00689	CcSEcCtD
Lisdexamfetamine—Affect lability—Betamethasone—ankylosing spondylitis	0.00689	0.00689	CcSEcCtD
Lisdexamfetamine—Psychotic disorder—Dexamethasone—ankylosing spondylitis	0.00683	0.00683	CcSEcCtD
Lisdexamfetamine—Psychotic disorder—Betamethasone—ankylosing spondylitis	0.00683	0.00683	CcSEcCtD
Lisdexamfetamine—Irritability—Dexamethasone—ankylosing spondylitis	0.00668	0.00668	CcSEcCtD
Lisdexamfetamine—Irritability—Betamethasone—ankylosing spondylitis	0.00668	0.00668	CcSEcCtD
Lisdexamfetamine—Weight increased—Prednisolone—ankylosing spondylitis	0.00659	0.00659	CcSEcCtD
Lisdexamfetamine—Acute coronary syndrome—Prednisolone—ankylosing spondylitis	0.00637	0.00637	CcSEcCtD
Lisdexamfetamine—Myocardial infarction—Prednisolone—ankylosing spondylitis	0.00633	0.00633	CcSEcCtD
Lisdexamfetamine—Weight increased—Triamcinolone—ankylosing spondylitis	0.00606	0.00606	CcSEcCtD
Lisdexamfetamine—Weight increased—Methylprednisolone—ankylosing spondylitis	0.00605	0.00605	CcSEcCtD
Lisdexamfetamine—Affect lability—Prednisone—ankylosing spondylitis	0.006	0.006	CcSEcCtD
Lisdexamfetamine—Psychotic disorder—Prednisone—ankylosing spondylitis	0.00595	0.00595	CcSEcCtD
Lisdexamfetamine—Acute coronary syndrome—Triamcinolone—ankylosing spondylitis	0.00586	0.00586	CcSEcCtD
Lisdexamfetamine—Acute coronary syndrome—Methylprednisolone—ankylosing spondylitis	0.00584	0.00584	CcSEcCtD
Lisdexamfetamine—Myocardial infarction—Triamcinolone—ankylosing spondylitis	0.00582	0.00582	CcSEcCtD
Lisdexamfetamine—Irritability—Prednisone—ankylosing spondylitis	0.00581	0.00581	CcSEcCtD
Lisdexamfetamine—Myocardial infarction—Methylprednisolone—ankylosing spondylitis	0.00581	0.00581	CcSEcCtD
Lisdexamfetamine—Visual impairment—Prednisolone—ankylosing spondylitis	0.00559	0.00559	CcSEcCtD
Lisdexamfetamine—Weight increased—Dexamethasone—ankylosing spondylitis	0.0055	0.0055	CcSEcCtD
Lisdexamfetamine—Weight increased—Betamethasone—ankylosing spondylitis	0.0055	0.0055	CcSEcCtD
Lisdexamfetamine—Weight decreased—Betamethasone—ankylosing spondylitis	0.00547	0.00547	CcSEcCtD
Lisdexamfetamine—Weight decreased—Dexamethasone—ankylosing spondylitis	0.00547	0.00547	CcSEcCtD
Lisdexamfetamine—Visual disturbance—Methotrexate—ankylosing spondylitis	0.00537	0.00537	CcSEcCtD
Lisdexamfetamine—Acute coronary syndrome—Dexamethasone—ankylosing spondylitis	0.00531	0.00531	CcSEcCtD
Lisdexamfetamine—Acute coronary syndrome—Betamethasone—ankylosing spondylitis	0.00531	0.00531	CcSEcCtD
Lisdexamfetamine—Hallucination—Methylprednisolone—ankylosing spondylitis	0.0053	0.0053	CcSEcCtD
Lisdexamfetamine—Myocardial infarction—Betamethasone—ankylosing spondylitis	0.00528	0.00528	CcSEcCtD
Lisdexamfetamine—Myocardial infarction—Dexamethasone—ankylosing spondylitis	0.00528	0.00528	CcSEcCtD
Lisdexamfetamine—Cerebrovascular accident—Methotrexate—ankylosing spondylitis	0.0052	0.0052	CcSEcCtD
Lisdexamfetamine—Visual impairment—Methylprednisolone—ankylosing spondylitis	0.00513	0.00513	CcSEcCtD
Lisdexamfetamine—Eye disorder—Methylprednisolone—ankylosing spondylitis	0.00497	0.00497	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Methylprednisolone—ankylosing spondylitis	0.00494	0.00494	CcSEcCtD
Lisdexamfetamine—Irritability—Methotrexate—ankylosing spondylitis	0.00486	0.00486	CcSEcCtD
Lisdexamfetamine—Erectile dysfunction—Prednisone—ankylosing spondylitis	0.00485	0.00485	CcSEcCtD
Lisdexamfetamine—Hallucination—Betamethasone—ankylosing spondylitis	0.00482	0.00482	CcSEcCtD
Lisdexamfetamine—Hallucination—Dexamethasone—ankylosing spondylitis	0.00482	0.00482	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Methylprednisolone—ankylosing spondylitis	0.00481	0.00481	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Methylprednisolone—ankylosing spondylitis	0.0048	0.0048	CcSEcCtD
Lisdexamfetamine—Weight increased—Prednisone—ankylosing spondylitis	0.00479	0.00479	CcSEcCtD
Lisdexamfetamine—Weight decreased—Prednisone—ankylosing spondylitis	0.00476	0.00476	CcSEcCtD
Lisdexamfetamine—Vision blurred—Prednisolone—ankylosing spondylitis	0.00476	0.00476	CcSEcCtD
Lisdexamfetamine—Depression—Prednisone—ankylosing spondylitis	0.00468	0.00468	CcSEcCtD
Lisdexamfetamine—Visual impairment—Betamethasone—ankylosing spondylitis	0.00466	0.00466	CcSEcCtD
Lisdexamfetamine—Visual impairment—Dexamethasone—ankylosing spondylitis	0.00466	0.00466	CcSEcCtD
Lisdexamfetamine—Mental disorder—Methylprednisolone—ankylosing spondylitis	0.00466	0.00466	CcSEcCtD
Lisdexamfetamine—Malnutrition—Methylprednisolone—ankylosing spondylitis	0.00463	0.00463	CcSEcCtD
Lisdexamfetamine—Acute coronary syndrome—Prednisone—ankylosing spondylitis	0.00463	0.00463	CcSEcCtD
Lisdexamfetamine—Angioedema—Prednisolone—ankylosing spondylitis	0.00461	0.00461	CcSEcCtD
Lisdexamfetamine—Myocardial infarction—Prednisone—ankylosing spondylitis	0.0046	0.0046	CcSEcCtD
Lisdexamfetamine—Toxic epidermal necrolysis—Methotrexate—ankylosing spondylitis	0.00458	0.00458	CcSEcCtD
Lisdexamfetamine—Eye disorder—Dexamethasone—ankylosing spondylitis	0.00452	0.00452	CcSEcCtD
Lisdexamfetamine—Eye disorder—Betamethasone—ankylosing spondylitis	0.00452	0.00452	CcSEcCtD
Lisdexamfetamine—Convulsion—Prednisolone—ankylosing spondylitis	0.00437	0.00437	CcSEcCtD
Lisdexamfetamine—Hypertension—Prednisolone—ankylosing spondylitis	0.00436	0.00436	CcSEcCtD
Lisdexamfetamine—Angioedema—Triamcinolone—ankylosing spondylitis	0.00424	0.00424	CcSEcCtD
Lisdexamfetamine—Angioedema—Methylprednisolone—ankylosing spondylitis	0.00423	0.00423	CcSEcCtD
Lisdexamfetamine—Hallucination—Prednisone—ankylosing spondylitis	0.00419	0.00419	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Prednisolone—ankylosing spondylitis	0.00412	0.00412	CcSEcCtD
Lisdexamfetamine—Erectile dysfunction—Methotrexate—ankylosing spondylitis	0.00405	0.00405	CcSEcCtD
Lisdexamfetamine—Convulsion—Triamcinolone—ankylosing spondylitis	0.00402	0.00402	CcSEcCtD
Lisdexamfetamine—Tachycardia—Prednisolone—ankylosing spondylitis	0.00402	0.00402	CcSEcCtD
Lisdexamfetamine—Convulsion—Methylprednisolone—ankylosing spondylitis	0.00401	0.00401	CcSEcCtD
Lisdexamfetamine—Hypertension—Triamcinolone—ankylosing spondylitis	0.00401	0.00401	CcSEcCtD
Lisdexamfetamine—Hypertension—Methylprednisolone—ankylosing spondylitis	0.004	0.004	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Prednisolone—ankylosing spondylitis	0.00398	0.00398	CcSEcCtD
Lisdexamfetamine—Eye disorder—Prednisone—ankylosing spondylitis	0.00394	0.00394	CcSEcCtD
Lisdexamfetamine—Anxiety—Methylprednisolone—ankylosing spondylitis	0.00393	0.00393	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—ankylosing spondylitis	0.00392	0.00392	CcSEcCtD
Lisdexamfetamine—Depression—Methotrexate—ankylosing spondylitis	0.00391	0.00391	CcSEcCtD
Lisdexamfetamine—Stevens-Johnson syndrome—Methotrexate—ankylosing spondylitis	0.00389	0.00389	CcSEcCtD
Lisdexamfetamine—Dry mouth—Triamcinolone—ankylosing spondylitis	0.00387	0.00387	CcSEcCtD
Lisdexamfetamine—Angioedema—Betamethasone—ankylosing spondylitis	0.00385	0.00385	CcSEcCtD
Lisdexamfetamine—Angioedema—Dexamethasone—ankylosing spondylitis	0.00385	0.00385	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Prednisone—ankylosing spondylitis	0.00381	0.00381	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Triamcinolone—ankylosing spondylitis	0.00379	0.00379	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Methylprednisolone—ankylosing spondylitis	0.00378	0.00378	CcSEcCtD
Lisdexamfetamine—Insomnia—Prednisolone—ankylosing spondylitis	0.00373	0.00373	CcSEcCtD
Lisdexamfetamine—Hepatobiliary disease—Methotrexate—ankylosing spondylitis	0.00371	0.00371	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Methylprednisolone—ankylosing spondylitis	0.00371	0.00371	CcSEcCtD
Lisdexamfetamine—Tachycardia—Triamcinolone—ankylosing spondylitis	0.0037	0.0037	CcSEcCtD
Lisdexamfetamine—Mental disorder—Prednisone—ankylosing spondylitis	0.00369	0.00369	CcSEcCtD
Lisdexamfetamine—Tachycardia—Methylprednisolone—ankylosing spondylitis	0.00369	0.00369	CcSEcCtD
Lisdexamfetamine—Skin disorder—Methylprednisolone—ankylosing spondylitis	0.00367	0.00367	CcSEcCtD
Lisdexamfetamine—Malnutrition—Prednisone—ankylosing spondylitis	0.00367	0.00367	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Triamcinolone—ankylosing spondylitis	0.00366	0.00366	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Methylprednisolone—ankylosing spondylitis	0.00366	0.00366	CcSEcCtD
Lisdexamfetamine—Convulsion—Betamethasone—ankylosing spondylitis	0.00365	0.00365	CcSEcCtD
Lisdexamfetamine—Convulsion—Dexamethasone—ankylosing spondylitis	0.00365	0.00365	CcSEcCtD
Lisdexamfetamine—Hypertension—Betamethasone—ankylosing spondylitis	0.00364	0.00364	CcSEcCtD
Lisdexamfetamine—Hypertension—Dexamethasone—ankylosing spondylitis	0.00364	0.00364	CcSEcCtD
Lisdexamfetamine—Anxiety—Dexamethasone—ankylosing spondylitis	0.00357	0.00357	CcSEcCtD
Lisdexamfetamine—Anxiety—Betamethasone—ankylosing spondylitis	0.00357	0.00357	CcSEcCtD
Lisdexamfetamine—Hepatitis—Methotrexate—ankylosing spondylitis	0.00352	0.00352	CcSEcCtD
Lisdexamfetamine—Vision blurred—Prednisone—ankylosing spondylitis	0.00346	0.00346	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Betamethasone—ankylosing spondylitis	0.00344	0.00344	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Dexamethasone—ankylosing spondylitis	0.00344	0.00344	CcSEcCtD
Lisdexamfetamine—Insomnia—Triamcinolone—ankylosing spondylitis	0.00343	0.00343	CcSEcCtD
Lisdexamfetamine—Insomnia—Methylprednisolone—ankylosing spondylitis	0.00342	0.00342	CcSEcCtD
Lisdexamfetamine—Visual impairment—Methotrexate—ankylosing spondylitis	0.00339	0.00339	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Triamcinolone—ankylosing spondylitis	0.00338	0.00338	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Dexamethasone—ankylosing spondylitis	0.00337	0.00337	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Betamethasone—ankylosing spondylitis	0.00337	0.00337	CcSEcCtD
Lisdexamfetamine—Agitation—Prednisone—ankylosing spondylitis	0.00337	0.00337	CcSEcCtD
Lisdexamfetamine—Tachycardia—Dexamethasone—ankylosing spondylitis	0.00336	0.00336	CcSEcCtD
Lisdexamfetamine—Tachycardia—Betamethasone—ankylosing spondylitis	0.00336	0.00336	CcSEcCtD
Lisdexamfetamine—Angioedema—Prednisone—ankylosing spondylitis	0.00335	0.00335	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Triamcinolone—ankylosing spondylitis	0.00334	0.00334	CcSEcCtD
Lisdexamfetamine—Erythema multiforme—Methotrexate—ankylosing spondylitis	0.00333	0.00333	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Methylprednisolone—ankylosing spondylitis	0.00333	0.00333	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Betamethasone—ankylosing spondylitis	0.00332	0.00332	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Dexamethasone—ankylosing spondylitis	0.00332	0.00332	CcSEcCtD
Lisdexamfetamine—Eye disorder—Methotrexate—ankylosing spondylitis	0.00329	0.00329	CcSEcCtD
Lisdexamfetamine—Anorexia—Dexamethasone—ankylosing spondylitis	0.00328	0.00328	CcSEcCtD
Lisdexamfetamine—Anorexia—Betamethasone—ankylosing spondylitis	0.00328	0.00328	CcSEcCtD
Lisdexamfetamine—Urticaria—Prednisolone—ankylosing spondylitis	0.00327	0.00327	CcSEcCtD
Lisdexamfetamine—Cardiac disorder—Methotrexate—ankylosing spondylitis	0.00327	0.00327	CcSEcCtD
Lisdexamfetamine—Fatigue—Triamcinolone—ankylosing spondylitis	0.00327	0.00327	CcSEcCtD
Lisdexamfetamine—Fatigue—Methylprednisolone—ankylosing spondylitis	0.00326	0.00326	CcSEcCtD
Lisdexamfetamine—Immune system disorder—Methotrexate—ankylosing spondylitis	0.00318	0.00318	CcSEcCtD
Lisdexamfetamine—Convulsion—Prednisone—ankylosing spondylitis	0.00318	0.00318	CcSEcCtD
Lisdexamfetamine—Mediastinal disorder—Methotrexate—ankylosing spondylitis	0.00317	0.00317	CcSEcCtD
Lisdexamfetamine—Hypertension—Prednisone—ankylosing spondylitis	0.00317	0.00317	CcSEcCtD
Lisdexamfetamine—Anxiety—Prednisone—ankylosing spondylitis	0.00311	0.00311	CcSEcCtD
Lisdexamfetamine—Insomnia—Betamethasone—ankylosing spondylitis	0.00311	0.00311	CcSEcCtD
Lisdexamfetamine—Insomnia—Dexamethasone—ankylosing spondylitis	0.00311	0.00311	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—ankylosing spondylitis	0.0031	0.0031	CcSEcCtD
Lisdexamfetamine—Mental disorder—Methotrexate—ankylosing spondylitis	0.00309	0.00309	CcSEcCtD
Lisdexamfetamine—Malnutrition—Methotrexate—ankylosing spondylitis	0.00307	0.00307	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Prednisolone—ankylosing spondylitis	0.00304	0.00304	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Dexamethasone—ankylosing spondylitis	0.00303	0.00303	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Betamethasone—ankylosing spondylitis	0.00303	0.00303	CcSEcCtD
Lisdexamfetamine—Urticaria—Triamcinolone—ankylosing spondylitis	0.00301	0.00301	CcSEcCtD
Lisdexamfetamine—Urticaria—Methylprednisolone—ankylosing spondylitis	0.003	0.003	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Triamcinolone—ankylosing spondylitis	0.003	0.003	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Prednisone—ankylosing spondylitis	0.00299	0.00299	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Dexamethasone—ankylosing spondylitis	0.00299	0.00299	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Betamethasone—ankylosing spondylitis	0.00299	0.00299	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Betamethasone—ankylosing spondylitis	0.00297	0.00297	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Dexamethasone—ankylosing spondylitis	0.00297	0.00297	CcSEcCtD
Lisdexamfetamine—Fatigue—Betamethasone—ankylosing spondylitis	0.00296	0.00296	CcSEcCtD
Lisdexamfetamine—Fatigue—Dexamethasone—ankylosing spondylitis	0.00296	0.00296	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Prednisone—ankylosing spondylitis	0.00294	0.00294	CcSEcCtD
Lisdexamfetamine—Tachycardia—Prednisone—ankylosing spondylitis	0.00292	0.00292	CcSEcCtD
Lisdexamfetamine—Skin disorder—Prednisone—ankylosing spondylitis	0.00291	0.00291	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Prednisone—ankylosing spondylitis	0.00289	0.00289	CcSEcCtD
Lisdexamfetamine—Vision blurred—Methotrexate—ankylosing spondylitis	0.00289	0.00289	CcSEcCtD
Lisdexamfetamine—Anorexia—Prednisone—ankylosing spondylitis	0.00285	0.00285	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Triamcinolone—ankylosing spondylitis	0.00279	0.00279	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Methylprednisolone—ankylosing spondylitis	0.00279	0.00279	CcSEcCtD
Lisdexamfetamine—Urticaria—Betamethasone—ankylosing spondylitis	0.00273	0.00273	CcSEcCtD
Lisdexamfetamine—Urticaria—Dexamethasone—ankylosing spondylitis	0.00273	0.00273	CcSEcCtD
Lisdexamfetamine—Dizziness—Prednisolone—ankylosing spondylitis	0.00272	0.00272	CcSEcCtD
Lisdexamfetamine—Asthenia—Triamcinolone—ankylosing spondylitis	0.00272	0.00272	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Betamethasone—ankylosing spondylitis	0.00272	0.00272	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Dexamethasone—ankylosing spondylitis	0.00272	0.00272	CcSEcCtD
Lisdexamfetamine—Asthenia—Methylprednisolone—ankylosing spondylitis	0.00271	0.00271	CcSEcCtD
Lisdexamfetamine—Insomnia—Prednisone—ankylosing spondylitis	0.00271	0.00271	CcSEcCtD
Lisdexamfetamine—Convulsion—Methotrexate—ankylosing spondylitis	0.00266	0.00266	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Prednisone—ankylosing spondylitis	0.00264	0.00264	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Prednisone—ankylosing spondylitis	0.0026	0.0026	CcSEcCtD
Lisdexamfetamine—Rash—Prednisolone—ankylosing spondylitis	0.0026	0.0026	CcSEcCtD
Lisdexamfetamine—Dermatitis—Prednisolone—ankylosing spondylitis	0.0026	0.0026	CcSEcCtD
Lisdexamfetamine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—ankylosing spondylitis	0.00259	0.00259	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Methylprednisolone—ankylosing spondylitis	0.00259	0.00259	CcSEcCtD
Lisdexamfetamine—Fatigue—Prednisone—ankylosing spondylitis	0.00258	0.00258	CcSEcCtD
Lisdexamfetamine—Headache—Prednisolone—ankylosing spondylitis	0.00258	0.00258	CcSEcCtD
Lisdexamfetamine—Constipation—Prednisone—ankylosing spondylitis	0.00256	0.00256	CcSEcCtD
Lisdexamfetamine—Dizziness—Triamcinolone—ankylosing spondylitis	0.00251	0.00251	CcSEcCtD
Lisdexamfetamine—Anaphylactic shock—Methotrexate—ankylosing spondylitis	0.0025	0.0025	CcSEcCtD
Lisdexamfetamine—Dizziness—Methylprednisolone—ankylosing spondylitis	0.0025	0.0025	CcSEcCtD
Lisdexamfetamine—Asthenia—Betamethasone—ankylosing spondylitis	0.00247	0.00247	CcSEcCtD
Lisdexamfetamine—Asthenia—Dexamethasone—ankylosing spondylitis	0.00247	0.00247	CcSEcCtD
Lisdexamfetamine—Nervous system disorder—Methotrexate—ankylosing spondylitis	0.00245	0.00245	CcSEcCtD
Lisdexamfetamine—Nausea—Prednisolone—ankylosing spondylitis	0.00245	0.00245	CcSEcCtD
Lisdexamfetamine—Skin disorder—Methotrexate—ankylosing spondylitis	0.00243	0.00243	CcSEcCtD
Lisdexamfetamine—Hyperhidrosis—Methotrexate—ankylosing spondylitis	0.00242	0.00242	CcSEcCtD
Lisdexamfetamine—Vomiting—Triamcinolone—ankylosing spondylitis	0.00241	0.00241	CcSEcCtD
Lisdexamfetamine—Vomiting—Methylprednisolone—ankylosing spondylitis	0.0024	0.0024	CcSEcCtD
Lisdexamfetamine—Rash—Triamcinolone—ankylosing spondylitis	0.00239	0.00239	CcSEcCtD
Lisdexamfetamine—Dermatitis—Triamcinolone—ankylosing spondylitis	0.00239	0.00239	CcSEcCtD
Lisdexamfetamine—Anorexia—Methotrexate—ankylosing spondylitis	0.00239	0.00239	CcSEcCtD
Lisdexamfetamine—Rash—Methylprednisolone—ankylosing spondylitis	0.00238	0.00238	CcSEcCtD
Lisdexamfetamine—Dermatitis—Methylprednisolone—ankylosing spondylitis	0.00238	0.00238	CcSEcCtD
Lisdexamfetamine—Urticaria—Prednisone—ankylosing spondylitis	0.00238	0.00238	CcSEcCtD
Lisdexamfetamine—Headache—Triamcinolone—ankylosing spondylitis	0.00237	0.00237	CcSEcCtD
Lisdexamfetamine—Headache—Methylprednisolone—ankylosing spondylitis	0.00237	0.00237	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Prednisone—ankylosing spondylitis	0.00237	0.00237	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Dexamethasone—ankylosing spondylitis	0.00235	0.00235	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Betamethasone—ankylosing spondylitis	0.00235	0.00235	CcSEcCtD
Lisdexamfetamine—Dizziness—Dexamethasone—ankylosing spondylitis	0.00227	0.00227	CcSEcCtD
Lisdexamfetamine—Dizziness—Betamethasone—ankylosing spondylitis	0.00227	0.00227	CcSEcCtD
Lisdexamfetamine—Insomnia—Methotrexate—ankylosing spondylitis	0.00226	0.00226	CcSEcCtD
Lisdexamfetamine—Nausea—Triamcinolone—ankylosing spondylitis	0.00225	0.00225	CcSEcCtD
Lisdexamfetamine—Nausea—Methylprednisolone—ankylosing spondylitis	0.00225	0.00225	CcSEcCtD
Lisdexamfetamine—Dyspnoea—Methotrexate—ankylosing spondylitis	0.00223	0.00223	CcSEcCtD
Lisdexamfetamine—Somnolence—Methotrexate—ankylosing spondylitis	0.00222	0.00222	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Prednisone—ankylosing spondylitis	0.00221	0.00221	CcSEcCtD
Lisdexamfetamine—Dyspepsia—Methotrexate—ankylosing spondylitis	0.0022	0.0022	CcSEcCtD
Lisdexamfetamine—Vomiting—Dexamethasone—ankylosing spondylitis	0.00219	0.00219	CcSEcCtD
Lisdexamfetamine—Vomiting—Betamethasone—ankylosing spondylitis	0.00219	0.00219	CcSEcCtD
Lisdexamfetamine—Decreased appetite—Methotrexate—ankylosing spondylitis	0.00218	0.00218	CcSEcCtD
Lisdexamfetamine—Rash—Dexamethasone—ankylosing spondylitis	0.00217	0.00217	CcSEcCtD
Lisdexamfetamine—Rash—Betamethasone—ankylosing spondylitis	0.00217	0.00217	CcSEcCtD
Lisdexamfetamine—Dermatitis—Dexamethasone—ankylosing spondylitis	0.00217	0.00217	CcSEcCtD
Lisdexamfetamine—Dermatitis—Betamethasone—ankylosing spondylitis	0.00217	0.00217	CcSEcCtD
Lisdexamfetamine—Gastrointestinal disorder—Methotrexate—ankylosing spondylitis	0.00216	0.00216	CcSEcCtD
Lisdexamfetamine—Fatigue—Methotrexate—ankylosing spondylitis	0.00216	0.00216	CcSEcCtD
Lisdexamfetamine—Headache—Betamethasone—ankylosing spondylitis	0.00215	0.00215	CcSEcCtD
Lisdexamfetamine—Headache—Dexamethasone—ankylosing spondylitis	0.00215	0.00215	CcSEcCtD
Lisdexamfetamine—Asthenia—Prednisone—ankylosing spondylitis	0.00215	0.00215	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Prednisone—ankylosing spondylitis	0.00205	0.00205	CcSEcCtD
Lisdexamfetamine—Nausea—Dexamethasone—ankylosing spondylitis	0.00204	0.00204	CcSEcCtD
Lisdexamfetamine—Nausea—Betamethasone—ankylosing spondylitis	0.00204	0.00204	CcSEcCtD
Lisdexamfetamine—Urticaria—Methotrexate—ankylosing spondylitis	0.00199	0.00199	CcSEcCtD
Lisdexamfetamine—Dizziness—Prednisone—ankylosing spondylitis	0.00198	0.00198	CcSEcCtD
Lisdexamfetamine—Body temperature increased—Methotrexate—ankylosing spondylitis	0.00198	0.00198	CcSEcCtD
Lisdexamfetamine—Vomiting—Prednisone—ankylosing spondylitis	0.0019	0.0019	CcSEcCtD
Lisdexamfetamine—Rash—Prednisone—ankylosing spondylitis	0.00189	0.00189	CcSEcCtD
Lisdexamfetamine—Dermatitis—Prednisone—ankylosing spondylitis	0.00189	0.00189	CcSEcCtD
Lisdexamfetamine—Headache—Prednisone—ankylosing spondylitis	0.00188	0.00188	CcSEcCtD
Lisdexamfetamine—Hypersensitivity—Methotrexate—ankylosing spondylitis	0.00184	0.00184	CcSEcCtD
Lisdexamfetamine—Asthenia—Methotrexate—ankylosing spondylitis	0.0018	0.0018	CcSEcCtD
Lisdexamfetamine—Nausea—Prednisone—ankylosing spondylitis	0.00178	0.00178	CcSEcCtD
Lisdexamfetamine—Diarrhoea—Methotrexate—ankylosing spondylitis	0.00171	0.00171	CcSEcCtD
Lisdexamfetamine—Dizziness—Methotrexate—ankylosing spondylitis	0.00165	0.00165	CcSEcCtD
Lisdexamfetamine—Vomiting—Methotrexate—ankylosing spondylitis	0.00159	0.00159	CcSEcCtD
Lisdexamfetamine—Rash—Methotrexate—ankylosing spondylitis	0.00158	0.00158	CcSEcCtD
Lisdexamfetamine—Dermatitis—Methotrexate—ankylosing spondylitis	0.00158	0.00158	CcSEcCtD
Lisdexamfetamine—Headache—Methotrexate—ankylosing spondylitis	0.00157	0.00157	CcSEcCtD
Lisdexamfetamine—Nausea—Methotrexate—ankylosing spondylitis	0.00149	0.00149	CcSEcCtD
